Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$0.09.

  • CytomX Therapeutics' EPS (Basic) fell 22857.14% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.41, marking a year-over-year increase of 14117.65%. This contributed to the annual value of $0.38 for FY2024, which is 390000.0% up from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' EPS (Basic) is -$0.09, which was down 22857.14% from $0.27 recorded in Q1 2025.
  • CytomX Therapeutics' 5-year EPS (Basic) high stood at $0.27 for Q1 2025, and its period low was -$0.53 during Q4 2021.
  • Over the past 5 years, CytomX Therapeutics' median EPS (Basic) value was -$0.08 (recorded in 2024), while the average stood at -$0.15.
  • Examining YoY changes over the last 5 years, CytomX Therapeutics' EPS (Basic) showed a top increase of 220000.0% in 2024 and a maximum decrease of 30000.0% in 2024.
  • Quarter analysis of 5 years shows CytomX Therapeutics' EPS (Basic) stood at -$0.53 in 2021, then skyrocketed by 75.62% to -$0.13 in 2022, then surged by 107.69% to $0.01 in 2023, then soared by 2200.0% to $0.23 in 2024, then crashed by 139.13% to -$0.09 in 2025.
  • Its last three reported values are -$0.09 in Q3 2025, $0.27 for Q1 2025, and $0.23 during Q4 2024.